Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles ...

It's quite possible for the new year to fulfill this ambitious name. Investing $122,100 in these three high-yield dividend ...

The price hikes come even as the Trump administration pressures pharmaceutical companies to lower costs for patients and ...

The costs of at least 350 drugs in the U.S. are expected to rise in 2026, according to a new analysis, despite many of the ...

Given the stock's less-than favorable performance during the last few years as it emerged from its pandemic growth days and ...

GSK (GSK) and other leading drugmakers plans to raise prices of as many as 350 medicines next year, with a median hike of ...

On December 16, Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy, starting in 2026. The company ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...